Brokerages Set Illumina, Inc. (NASDAQ:ILMN) PT at $158.57

Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus rating of “Hold” from the twenty-one ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $158.57.

Several research firms have recently commented on ILMN. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. Citigroup upgraded Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price target for the company in a research report on Wednesday, July 10th. Jefferies Financial Group began coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. Royal Bank of Canada decreased their target price on Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a report on Monday, July 1st. Finally, StockNews.com began coverage on Illumina in a report on Sunday, June 30th. They issued a “buy” rating for the company.

Illumina Trading Down 3.8 %

Shares of Illumina stock opened at $117.70 on Monday. The firm has a market capitalization of $18.75 billion, a price-to-earnings ratio of -14.44 and a beta of 1.15. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $195.64. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a 50 day moving average of $111.29 and a 200 day moving average of $123.67.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.08 earnings per share. As a group, research analysts predict that Illumina will post 1.5 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bouvel Investment Partners LLC grew its holdings in shares of Illumina by 1.3% during the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after buying an additional 84 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after acquiring an additional 88 shares in the last quarter. STF Management LP boosted its stake in shares of Illumina by 3.5% during the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 90 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Illumina by 12.3% during the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after acquiring an additional 94 shares in the last quarter. Finally, Gulf International Bank UK Ltd boosted its stake in shares of Illumina by 0.7% during the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after acquiring an additional 98 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.